Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study

BMC Neurol. 2009 Jun 10;9:23. doi: 10.1186/1471-2377-9-23.

Abstract

Background: Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed.

Methods: Eighty PD patients with psychotic episodes were compared to an age-matched control group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study.

Results: We found a positive correlation between psychotic episodes and dementia, number of concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio, levodopa the lowest. An adjusted logistic regression model confirmed the strong association with psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and 0.11, respectively).

Conclusion: The analysis indicates that dementia and concomitant medication are factors in PD associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly different associations with psychotic symptoms.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Case-Control Studies
  • Cross-Sectional Studies
  • Dopamine Agonists / adverse effects*
  • Dopamine Agonists / therapeutic use*
  • Female
  • Humans
  • Logistic Models
  • Male
  • Mental Disorders / chemically induced*
  • Mental Disorders / epidemiology*
  • Odds Ratio
  • Parkinson Disease / drug therapy*
  • Retrospective Studies

Substances

  • Dopamine Agonists